ACM
CMMB

ADAR1 Capital Management’s Chemomab Therapeutics CMMB Stock Holding History

ADAR1 Capital Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Hold
80,000
– – 0.01% 259
2026
Q1 		$126K Hold
80,000
– – 0.01% 279
2025
Q4 		$132K Buy
+80,000
New +$212K 0.01% 242

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ADAR1 Capital Management's CMMB Position: Q2 2026 in Review

ADAR1 Capital Management held its Chemomab Therapeutics (CMMB) position steady in Q2 2026 at 80,000 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #259.

ADAR1 Capital Management first reported a position in CMMB in Q4 2025 and has held it in 3 quarters since. The position peaked at $132K in Q4 2025. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • ADAR1 Capital Management held 80,000 shares of Chemomab Therapeutics worth $130K as of Q2 2026.
  • ADAR1 Capital Management left its Chemomab Therapeutics share count unchanged in Q2 2026.
  • Chemomab Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #259 holding.
  • ADAR1 Capital Management first reported a position in Chemomab Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • ADAR1 Capital Management's Chemomab Therapeutics position peaked at $132K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.